Mini Quiz: Suicide Risk in Veterans

Review finds ADHD drugs may ease perimenopause brain fog and improve daily focus, but objective cognition gains remain unclear; larger safety and efficacy studies needed.

An endocrinologist warns psychiatrists against overreading peripheral thyroid hormones and flags kelp and T3 microdosing as underrecognized risks.

Phase 2 trial finds bezisterim shows safety and symptom gains in long COVID, with strongest benefits for severe fatigue, PEM, and cognitive issues.

Adjustment disorder often goes undiagnosed after major life stressors, especially in cancer care; learn updated criteria, risks, and emerging therapies like psilocybin.

This study compared the efficacy and tolerability of the 5 second-generation antipsychotics that are currently FDA approved as adjunctive treatments for adults with MDD.

Real-world data show TRD costs spike during resistant episodes; Compass’ psilocybin COMP360 delivers durable symptom relief through 26 weeks, potentially easing resource strain.

Antipsychotic levels clarify adherence, guide dose escalation up to a point of futility, and offer more than pharmacogenetic testing, says Jonathan Meyer, MD.

Learn how clinicians tailor antidepressants by diagnosis, symptoms, adverse effects, and next-step strategies for treatment-resistant depression.